Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy

Novo Nordisk’s Chief Executive Lars Fruergaard Jorgensen talks to a journalist in Copenhagen

(Reuters) – The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.

(Reporting by Puyaan Singh in Bengaluru)